Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.

The Journal of clinical investigation - 1 Jun 2016

Lock Rebecca, Ingraham Rachel, Maertens Ophélia, Miller Abigail L, Weledji Nelly, Legius Eric, Konicek Bruce M, Yan Sau-Chi B, Graff Jeremy R, Cichowski Karen

Abstract excerpt

Neurofibromin 1-mutant (NF1-mutant) cancers are driven by excessive Ras signaling; however, there are currently no effective therapies for these or other Ras-dependent tumors. While combined MEK and mTORC1 suppression causes regression of NF1-deficient malignancies in animal models, the potential toxicity of cotargeting these 2 major signaling pathways in humans may necessitate the identification of more refined,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Genes, Neurofibromatosis 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to Mechanistic Target of Rapamycin Complex 1

Share to Multiprotein Complexes

Share to Nerve Sheath Neoplasms

Share to Neurofibromin 1

Share to Nucleocytoplasmic Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27159396
DOI: 10.1172/JCI85183
PMCID: PMC4887164

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.PMID 27159396Read ↗

Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors.Semantic proximity Read ↗

Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.Semantic proximity Read ↗

NF1 alterations in cancers: therapeutic implications in precision medicineSemantic proximity Read ↗

Dual inhibition of SHP2 and autophagy suppresses NF1-associated Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

MEK inhibition enhances the antitumor effect of radiation therapy in <i>NF1</i> -deficient glioblastomaSemantic proximity Read ↗

MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1 -Deficient GlioblastomaSemantic proximity Read ↗

New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.Semantic proximity Read ↗

Defining Key Signaling Nodes and Therapeutic Biomarkers in <i>NF1</i> -Mutant CancersSemantic proximity Read ↗

Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaSemantic proximity Read ↗

Neurofibromatosis-related tumors: emerging biology and therapies.Semantic proximity Read ↗

Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTsSemantic proximity Read ↗

NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma GrowthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.